动态监测上皮性卵巢癌患者血清CA125水平对疗效及预后的评估价值

目的:通过观察卵巢上皮性癌患者术前、术后及化疗后CA125水平变化,探讨其水平变化对患者预后的评价价值。方法:选取2012年3月至2013年2月间医院诊治的卵巢上皮性癌患者85例为研究对象,所有患者均接受规范的卵巢癌分期手术或卵巢癌细胞减灭术,术后常规进行系统化疗。比较手术及化疗后患者血清CA125水平的变化,分析患者血清CA125水平动态变化、转阴时间与患者预后关系。结果:治疗后,患者CA125水平呈明显下降趋势,差异具有统计学意义(P0.05)。T1/2≤20 d患者存活时间明显长于T1/220 d的患者,差异具有统计学意义(P0.05)。CA125转阴时间≤8周的患者存活时间长于CA125转阴时间8周的患者,差异具有统计学意义(P0.05)。其复发率明显低于CA125转阴时间8周的患者,复发时间长于CA125转阴时间8周的患者,差异具有统计学意义(P0.05)。结论:通过检测血清CA125水平变化可以对卵巢上皮性癌患者预后进行较为准确的评价。

Value of Dynamic Monitoring of Serum CA125 in Patients with Epithelial Ovarian Cancer to Evaluate the Efficacy and Prognosis of Patients with Epithelial Ovarian Cancer

ABSTRACT Objective: To investigate the value of CA125 levels on the clinical effects and prognosis of patients with epithelial ovari- an cancer. Methods: 85 cases with epithelial ovarian cancer who were treated with uterine plus bilateral accessory resection and chemotherapy in our hospital from March 2015 to March 2016 were selected as the study subjects. Then the serum levels of CA125 in patients before and after the treatment were observed and compared, and the relationship between the dynamic change of serum CA125, the clearance time and the prognosis of patients were analyzed. Results: The serum levels of CA125 significantly decreased after the treatment and the difference was statistically significant (P<0.05). The survival time of those whose T1/2 were less than 20 days was sig- nificantly longer than those of the patients with T1/2 more than 20 days, and the difference was statistically significant (P<0.05). The sur- vival time of those whose CA125 negative time were less than 8 weeks was longer than those of the patients with CA125 negative more than 8 weeks, and the difference was statistically significant (P<0.05). The recurrence rate was significantly lower than CA125 negative patients more than 8 weeks, and longer than those CA125 negative patients more than 8 weeks, and the differences were statistically sig- nificant (P<0.05). Conclusion: It is accurate to evaluate the prognosis of patients with epithelial ovarian cancer by detecting the change of serum levels of CA125.